Gene Therapy Trial for ApoE4 Homozygotes

User avatar
Julie G
Mod
Mod
Posts: 8368
Joined: Sat Oct 26, 2013 6:36 pm

Gene Therapy Trial for ApoE4 Homozygotes

Postby Julie G » Sat Sep 14, 2019 12:00 pm

The Department of Genetic Medicine at Weill Cornell Medicine would like to invite you to learn more about a gene therapy trial for individuals who are ApoE4/E4 and diagnosed with mild cognitive impairment (MCI) or Alzheimer’s disease (AD). The gene therapy is comprised of an adeno-associated virus gene transfer vector coding for ApoE2 which will be delivered intracisternally. The E2 allele is the rarest form of ApoE and carrying even one copy appears to reduce the risk of developing Alzheimer’s by up to 40%. The goal of the trial is to add the ApoE2 gene into the central nervous system to compensate for the effects of ApoE4, and thus prevent or delay the progression of AD.
 
The trial takes place in New York City and consists of an initial examination, the gene therapy administration and multiple follow-up visits over the course of a year. The initial examination will determine an individual’s eligibility to receive the gene therapy and includes a PET scan, an MRI scan and a spinal tap. For more information and a short video.
 
If you would like to learn more about the trial, contact Denesy Mancenido at: dem2026@med.cornell.edu.
 

Bettylacy
Senior Contributor
Senior Contributor
Posts: 114
Joined: Tue Jan 24, 2017 9:34 pm

Research Opportunity for 4/4's with MCI/AD

Postby Bettylacy » Thu Oct 24, 2019 1:22 pm

:D Hi all,

I just received this invitation and thought some of you might be interested or know someone.
Sending all my brothers, sisters and non binary friends a big hug!

Bettyg


I am a researcher at Weill Cornell Medicine and would like to invite you to collaborate with us in our gene therapy trial for APOE4 homozygotes.

Based on our studies over the past 6 years and the epidemiologic data that APOE2 confers benefits and decreases risk of AD, we are initiating a clinical trial using an adeno-associated virus gene transfer vector coding for human APOE2 to treat APOE4 homozygotes. The goal is convert the CNS from APOE4/E4 to APOE2/E4. The trial is an open label, dose-ranging study and will enroll individuals who are APOE4 homozygotes with clinical diagnosis of MCI or AD. The study is listed on clinicaltrials.gov: NCT03634007.

Do you have patients that may benefit from trial participation?

Best regards,
Denesy

Denesy Mancenido
Clinical Research Administrator
Director, Clinical Operations & Regulatory Affairs

Weill Cornell Medicine
Department of Genetic Medicine
1305 York Avenue, 13th Floor | New York, NY 10021
(P) 646.962.5583 | (F) 646.962.0380
dem2026@med.cornell.edu
APOe 3/4

Fiver
Senior Contributor
Senior Contributor
Posts: 544
Joined: Wed Feb 01, 2017 12:51 pm

Re: Gene Therapy Trial for ApoE4 Homozygotes

Postby Fiver » Fri Oct 25, 2019 8:49 am

Hi Julie and BettyLacy. Thanks. I'd been following this. At one point I saw that there was an age range criteria. I wondering if that's been dropped or expanded?
Four relatives with AD. Concerned, but hopeful. Introverted, but will talk about science.

NF52
Support Team
Support Team
Posts: 1136
Joined: Tue Oct 25, 2016 9:41 am
Location: Eastern U.S.

Re: Gene Therapy Trial for ApoE4 Homozygotes

Postby NF52 » Sat Oct 26, 2019 7:14 am

Fiver wrote:Hi Julie and BettyLacy. Thanks. I'd been following this. At one point I saw that there was an age range criteria. I wondering if that's been dropped or expanded?

The latest update of this Stage 1 trial was on October 14 on the NIH website: Clinical Trials. It continues to show several requirments, including Apoe 4/4, age 50 or older, diagnosis of MCI or any severity level of AD with positive amyloid on a PET scan. Informed consent can be given by the participant or a legally authorized individual. It does require the participant to be able to undergo MRI, PET and CSF (spinal tap) procedures and to not have heart failure, active infections, more than 4 cerebral micro-bleeds and various other disqualifying conditions.

Last month I spoke briefly with a researcher who said that ApoE 2 does confer some risks, including increased risk of diabetes. But this person also was excited by the concept of replacing some, but not all ApoE 4, with ApoE 2. I especially liked this person's comment that "We don't want to replace all ApoE4; it has some benefits itself."

A Stage 1 trial is for safety and efficacy of dosage amounts. It's where the really big risks are taken by participants in early-stage human trials. This one appears to have three dosing levels, and a 2 year commitment. for the 15 people who enroll. I admire anyone who decides to enroll.
4/4 and still an optimist!

Fiver
Senior Contributor
Senior Contributor
Posts: 544
Joined: Wed Feb 01, 2017 12:51 pm

Re: Gene Therapy Trial for ApoE4 Homozygotes

Postby Fiver » Sat Oct 26, 2019 7:17 am

Yes, those are the same criteria I saw. I don't qualify (yet). Thanks!
Four relatives with AD. Concerned, but hopeful. Introverted, but will talk about science.

mike
Senior Contributor
Senior Contributor
Posts: 626
Joined: Fri Mar 09, 2018 4:55 pm
Location: CA - Sonoma County

Re: Gene Therapy Trial for ApoE4 Homozygotes

Postby mike » Wed Oct 30, 2019 3:17 pm

I'm hoping to never qualify!
Sonoma Mike
4/4

Fiver
Senior Contributor
Senior Contributor
Posts: 544
Joined: Wed Feb 01, 2017 12:51 pm

Re: Gene Therapy Trial for ApoE4 Homozygotes

Postby Fiver » Mon Dec 02, 2019 10:16 am

Talked with Denesey, who seems very nice. While they might be flexible on the age requirement they are focusing only on individuals with some diagnosed MCI. Makes sense. They want to be able to show improvement, if it occurs. But they are still looking for participants.
Four relatives with AD. Concerned, but hopeful. Introverted, but will talk about science.


Return to “Announcements and Events”

Who is online

Users browsing this forum: No registered users and 1 guest